Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
I
use a lot more tamoxifen. Again, because I have this younger women
group, I think I didn’t apply tamoxifen as liberally in the
past as I do now – since I would use it pretty frequently for
women with positive receptors. You know, almost any tumor type –
even if you look again at this presentation we’re going to
hear from the NSABP – even the smallest tumors it looked like
there was some benefit from the tamoxifen. I think probably the
majority of younger women are going to be receptor-positive by our
modern definitions, which include immunohistochemistry and which
also include defining either positive estrogen receptor or positive
progesterone receptor as positive. I think that’s the other
thing that changed. A lot of our trials in the past looked only
at ER, whereas now in our trials, when we define receptor-negative,
you have to have both those things be negative, the sense is that
either positive is a positive.
Delayed
adjuvant tamoxifen in postmenopausal women with axillary node-negative
breast cancer: mortality over 10 years. Love RR, Olsen MR, Havighurst
TC. J Natl Cancer Inst. 1999 Jul 7;91(13):1167-8. No Abstract.
